Company Overview - Revvity, Inc. (RVTY) is a global life sciences and diagnostics company valued at $9.5 billion, providing instruments, reagents, software, and services for drug discovery, clinical research, and medical diagnostics [1] - The company specializes in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics [1] Market Position - RVTY is classified as a large-cap stock, with a market cap exceeding $10 billion, indicating its size, influence, and dominance in the diagnostics and research industry [2] - The company has a diversified product suite and recurring revenue streams, positioning it to benefit from growth in biotechnology, precision medicine, and global healthcare demand [2] Stock Performance - RVTY's stock has experienced a decline of 27.5% from its 52-week high of $118.30, reached on January 22 [3] - Over the past three months, RVTY stock has gained 10.9%, underperforming the S&P 500 Index, which fell by 3.3% [3] - On a six-month basis, RVTY shares rose by 1.1% but dipped 22% over the past 52 weeks, contrasting with the S&P 500's marginal gains and 16.4% returns over the last year [5] Market Trends and Analyst Sentiment - RVTY has been trading above its 50-day and 200-day moving averages, indicating a bearish trend [5] - Following the announcement of new global tariffs by the Trump administration, RVTY shares declined by 2.9%, raising concerns about potential disruptions to global supply chains and cost pressures [6] - Analysts maintain a "Moderate Buy" rating for RVTY, with a consensus mean price target of $119.40, suggesting a potential upside of 39.2% from current price levels [7]

Company Overview - Revvity, Inc. (RVTY) is a leading provider of health sciences solutions, technologies, and diagnostic services, headquartered in Waltham, Massachusetts, with a market cap of $10.3 billion [1] Stock Performance - RVTY shares have underperformed the broader market, declining 15% over the past year, while the S&P 500 Index has increased by nearly 12.3% [2] - In 2025, RVTY's stock fell 16.6%, contrasting with the S&P 500's 12.5% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7.5% year-to-date, RVTY's performance has been notably weaker [3] Financial Results - For Q3, RVTY reported revenue of $7 billion, reflecting a year-over-year increase of 2.2%, while adjusted EPS fell 7.8% to $1.18 [4] - Analysts project RVTY's EPS to grow marginally to $4.92 on a diluted basis for the current fiscal year ending in December [4] - RVTY has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [4] Analyst Ratings - Among 17 analysts covering RVTY, the consensus rating is a "Moderate Buy," consisting of nine "Strong Buy" ratings, one "Moderate Buy," and seven "Holds" [5] - Brandon Couillard from Wells Fargo maintained a "Hold" rating with a price target of $102, indicating a potential upside of 9.6% from current levels [6] - The mean price target of $113.07 suggests a 21.5% premium to RVTY's current price, while the highest price target of $135 indicates a potential upside of 45.1% [6]